v3.26.1
Description of Business, Organization and Liquidity - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Feb. 10, 2026
Feb. 09, 2026
Nov. 10, 2025
Mar. 31, 2026
Mar. 31, 2025
Feb. 08, 2026
Dec. 31, 2025
Description Of Business Organization And Liquidity [Line Items]              
Cash and cash equivalents       $ 532,899     $ 257,624
Accumulated deficit       515,146     487,363
Net loss       (27,783) $ (2,533)    
Cash flows from operating activities       (20,598) $ (2,439)    
Cash, cash equivalents and marketable securities             257,600
Current assets       535,408     260,423
Current liabilities       $ 23,812     $ 20,066
Common stock, authorized   500,000,000   500,000,000   300,000,000 300,000,000
Common stock, issued       60,303,212     1,597,321
Common stock, par value       $ 0.00001     $ 0.00001
Common Stock              
Description Of Business Organization And Liquidity [Line Items]              
Issuance of Series C preferred stock in PIPE, net of issuance costs (in shares)       16,644,737      
Underwriting Agreement              
Description Of Business Organization And Liquidity [Line Items]              
Sale of stock, number of shares issued in transaction 16,644,737            
Sale of stock, price per share $ 19            
Net proceeds from the underwritten offering $ 295,500            
Offering costs $ 20,800            
Over-Allotment Option | Underwriting Agreement              
Description Of Business Organization And Liquidity [Line Items]              
Sale of stock, number of shares issued in transaction 2,171,052            
Series B Non-Voting Convertible Preferred Stock              
Description Of Business Organization And Liquidity [Line Items]              
Preferred stock, issued       16,366     16,366
Preferred stock, par value       $ 0.00001     $ 0.00001
Number of preferred stock converted into common stock     1,000        
Series C Non-Voting Convertible Preferred Stock              
Description Of Business Organization And Liquidity [Line Items]              
Preferred stock, issued     43,882 1,877     43,882
Preferred stock, par value       $ 0.00001     $ 0.00001
Number of preferred stock converted into common stock   42,005 1,000        
Series C Preferred Stock              
Description Of Business Organization And Liquidity [Line Items]              
Number of preferred stock converted into common stock   42,005          
Series C Preferred Stock | Common Stock              
Description Of Business Organization And Liquidity [Line Items]              
Number of preferred stock converted into common stock   42,005,000          
Damora Therapeutics, Inc.              
Description Of Business Organization And Liquidity [Line Items]              
Asset acquisition, date of acquisition agreement     Nov. 10, 2025        
Common stock, issued     265,309        
Common stock, par value     $ 0.00001        
Damora Therapeutics, Inc. | Underwriting Agreement              
Description Of Business Organization And Liquidity [Line Items]              
Sale of stock, number of shares issued in transaction 16,644,737            
Sale of stock, price per share $ 19            
Net proceeds from the underwritten offering $ 295,500            
Offering costs $ 20,800            
Damora Therapeutics, Inc. | Over-Allotment Option | Underwriting Agreement              
Description Of Business Organization And Liquidity [Line Items]              
Sale of stock, number of shares issued in transaction 2,171,052            
Damora Therapeutics, Inc. | Series B Non-Voting Convertible Preferred Stock              
Description Of Business Organization And Liquidity [Line Items]              
Preferred stock, issued     16,366        
Preferred stock, par value     $ 0.00001        
Damora Therapeutics, Inc. | Series C Non-Voting Convertible Preferred Stock              
Description Of Business Organization And Liquidity [Line Items]              
Preferred stock, issued     4,241        
Preferred stock, par value     $ 0.00001        
Damora Therapeutics, Inc. | Series C Non-Voting Convertible Preferred Stock | Private Placement              
Description Of Business Organization And Liquidity [Line Items]              
Number of preferred stock converted into common stock     1,000        
Issuance of Series C preferred stock in PIPE, net of issuance costs (in shares)     39,641        
Gross proceeds from issuance of preferred stock in connection with private placement, net of issuance costs     $ 285,000        
Damora Therapeutics, Inc. | Series B and Series C Convertible Preferred Stock              
Description Of Business Organization And Liquidity [Line Items]              
Number of preferred stock converted into common stock     1,000